article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 99
article thumbnail

Absci and Kennedy Institute partner to expedite immunotherapies development

Pharmaceutical Technology

The collaboration will use the integrated drug creation platform of Absci and the clinical immunology datasets from the Kennedy Institute to identify antibodies to immune-mediated inflammatory diseases and autoimmune conditions with unprecedented speed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How SARS-CoV-2 hijacks human cells to evade immune system

Scienmag

Credit: UC San Diego Health Sciences Researchers at University of California San Diego School of Medicine have discovered one way in which SARS-CoV-2, the coronavirus that causes COVID-19, hijacks human cell machinery to blunt the immune response, allowing it to establish infection, replicate and cause disease.

article thumbnail

Chinese regulator approves personalised cancer vaccine trial

Drug Discovery World

Neoantigens are produced by specific tumour viruses, integrated into the genome and are abundantly expressed only in tumour cells with strong immunogenicity and tumour heterogeneity. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

article thumbnail

Rome Therapeutics raises $77m for junk DNA-targeting drugs

pharmaphorum

The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders.

DNA 52
article thumbnail

Using single-cell technology to create human antibody-based therapeutics

Drug Discovery World

The company is co-founded by former team leaders and multi-disciplinary tool builders from 10x Genomics. Taking a human-first approach, Infinimmune is leveraging single-cell technology to create truly human antibody-based therapeutics directly derived from the human immune system. This has consequences for safety and efficacy.

article thumbnail

Clamp2 provides vaccine hope for future pandemics

Drug Discovery World

Associate Professor Keith Chappell, co-leader of UQ’s Rapid Response Vaccine Pipeline, said pre-clinical testing had shown the ‘Clamp2’ platform was meeting all expectations, producing stabilised antigens and inducing strong neutralising immune responses. “We Clamp technology .